Declaration of conflict of interest. I have nothing to disclose.

Similar documents
Genetics of Sudden Cardiac Death. Geoffrey Pitt Ion Channel Research Unit Duke University. Disclosures: Grant funding from Medtronic.

Genetic testing in Cardiomyopathies

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Déclaration de Relations Professionnelles -Disclosure Statement of Financial Interest SPEAKER NAME. Nothing to disclose

In Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison

Effect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin

Familial DilatedCardiomyopathy Georgios K Efthimiadis, MD

Strength and weakness of genetic testing in clinical routine.

Silvia G Priori MD PhD

Clinical Genetics in Cardiomyopathies

Upgrade to Resynchronization Therapy. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016

Contribution of genetics for sudden death risk stratification in dilated cardiomyopathy

His Bundle Pacing in Bundle Branch Block May 11, 2017

Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.

Arrhythmogenic Cardiomyopathy cases. Δέσποινα Παρχαρίδου Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογική κλινική ΑΧΕΠΑ

Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure

at least 4 8 hours per week

EHRA/EUROPACE 2011 Madrid, Spain June

Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure

Cardiac Resynchronization Therapy for Heart Failure

Risk prediction in inherited conditions Laminopathies

Importance of CRT team for optimization of the results: a European point of view

Interventional solutions for atrial fibrillation in patients with heart failure

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

From left bundle branch block to cardiac failure

It has been shown from meta-analysis of randomized clinical trials that patients with a pre-crt QRS duration (QRSD) >150 ms benefit

Cardiac resynchronisation therapy (biventricular pacing) for the treatment of heart failure

LES NOUVEAUX TROUBLES DE CONDUCTION HEREDITAIRES

A CRITICAL MANIFESTATION OF HYPOTHYROIDISM W.S.R. TO ECG INDIFFERENT DEHAPRAKRITI

Update in Cardiomyopathies: Their New Classifications and Importance of Mixed Phenotypes

SEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers !

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine

Ventricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC

Cardiac Considerations and Care in Children with Neuromuscular Disorders

A rare variant in MYH6 confers high risk of sick sinus syndrome. Hilma Hólm ESC Congress 2011 Paris, France

Inherited Arrhythmia Syndromes

DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY. David SIU MD ( 蕭頌華醫生 ) Division of Cardiology The University of Hong Kong

LEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR?

Electrocardiographic abnormalities in patients with pulmonary sarcoidosis (RCD code: III)

Dysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias

Name of Presenter: Marwan Refaat, MD

The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125

Hypertrophic Cardiomyopathy: Patient Management in 2018

Breed specificities of Canine Dilated Cardiomyopathy Dr. Gerhard Wess

Gender and cardiac resynchronization therapy. Chairs: David Heaven & Belinda Green. Gender and Cardiac Resynchronisation Therapy

CRT in the RV Paced Patient When to Upgrade?

8/8/2011. CARDIAC RESYCHRONIZATION THERAPY for Heart Failure. Case Presentation. Case Presentation

Hypertrophic Cardiomyopathy

The Genetics and Prevention of Sudden Cardiac Death

Imaging in dilated cardiomyopathy : factors associated with a poor outcome

Πρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια:

Diploma in Electrocardiography

How to Approach the Patient with CRT and Recurrent Heart Failure

A Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE

Cardiac Resynchronization Therapy Guidelines and Missing Groups

C. Lutman, L. Vitali Serdoz, G. Barbati, E. Cadamuro, S. Magnani, M. Zecchin, M. Merlo, G. Sinagra

Heart Failure Overview. Dr Chris K Y Wong

Risk Stratification in Heart Failure: The Role of Emerging Biomarkers

Declaration of conflict of interest

Antony French Consultant Cardiologist & Electrophysiologist

ΜΥΟΚΑΡΔΙΟΠΑΘΕΙΕΣ. Ανεξήγητη βραδυκαρδία µε ή χωρίς διαταραχές κολποκοιλιακής αγωγής: τι µπορεί να κρύβει? ΕΦΗ Ι. ΠΡΑΠΠΑ Καρδιολόγος

ECG Underwriting Puzzler Dr. Regina Rosace AVP & Medical Director

Family Medicine for English language students of Medical University of Lodz ECG. Jakub Dorożyński

CKD Satellite Symposium

BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT

Noninvasive Predictors of Sudden Cardiac Death

Chapter 2 Practical Approach

TRATTAMENTO INTERVENTISTICO. Dr. Antonio Sagone

Genetics of Atrial Fibrillation: does it help in treatment decisions?

Hereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases

Impact of QRS duration and morphology on CRT effectiveness

Tachycardia-induced heart failure - Does it exist?

Earlier studies, mainly in rodents, have shown that diabetic

in Familial Dilated Cardiomyopathy

Cardiac Gene Therapy: Beyond the Mouse. David M Kaye Heart Failure Research Group Baker IDI, Melbourne, AUSTRALIA

Cardiomyopathy in Fabry s disease

Pearls of the ESC/ERS Guidelines 2015 Channelopathies

Tachycardia Devices Indications and Basic Trouble Shooting

ECG interpretation basics

Solutions for Every Day Problems Cardiologists and the ECG: Are We Really That Good at It? Part II Daniel José Piñeiro Profesor Titular de Medicina,

Biomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018

Corporate Medical Policy

Cardiac Resynchronization ICD Therapy: What is New?

From Bench to Practice: Cardiac Resynchronisation Therapy

Sudden cardiac death (SCD) accounts for 20% of mortality. Sudden Cardiac Death Compendium. Genetics of Sudden Cardiac Death

Left ventricular non-compaction: the New Cardiomyopathy on the Block

C. Quarta, L. Obici, S. Longhi, S. Perlini, A. Milandri, F. Del Corso, F. Perfetto, F. Cappelli, G. Merlini, C. Rapezzi

Definition and classification of the cardiomyopathies. Georgios K Efthimiadis Ass Prof of Cardiology

Cardiomyopathy. ACOI IM Board Review 2018 Martin C. Burke DO, FACOI

1. Cardiomyocytes and nonmyocyte. 2. Extracellular Matrix 3. Vessels שאלה 1. Pathobiology of Heart Failure Molecular and Cellular Mechanism

Silvia G Priori MD PhD

Gene annotation for heart rhythm. 1. Control of heart rate 2. Action Potential 3. Ion channels and transporters 4. Arrhythmia 5.

His Bundle Pacing: Where is it going? Kenneth A. Ellenbogen, M.D. Kontos Professor, VCU School of Medicine November 17, 2017

Electrical System Overview Electrocardiograms Action Potentials 12-Lead Positioning Values To Memorize Calculating Rates

This is What I do to Improve CRT Response for CRT Non-Responders

Appendix D Output Code and Interpretation of Analysis

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

Steel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015

Transcription:

Declaration of conflict of interest I have nothing to disclose.

Left Bundle branch block in HF: DO GENETICS MATTER? Silvia Giuliana Priori Cardiovascular Genetics, Langone Medical Center, New York University School of Medicine, New York, USA and Molecular Cardiology, IRCCS Fondazione Maugeri Dept of Cardiology, University of Pavia. Italy

QRS AND HEART FAILURE Nearly 5 million Americans suffer from heart failure (HF), and more than 250 000 die annually for the disease. Intraventricular conduction delay caused by asymmetrical contraction is present in 1/3 of HF patients and it may be an independent risk factor for death. LBB decreases regional loading, contractile work, myocardial blood flow, and oxygen consumption in the early-activated anterior myocardium, whereas these parameters are increased in the late-activated lateral LV. CRT improves contractile synchrony, systolic function and rehomogenizes regional workload.

Genetics and LBBB in HF The question whether genetic abnormalities are part of the interaction between conduction delay/dyssynchrony and increased mortality is an important one. Two aspects need to be discussed: 1) Role of the genome: is there a genetic predisposition to develop LBBB? 2) Changes in the trascriptome: Do genetic factors account for the effect of LBBB on prognosis?

Is there a genetic predisposition to develop LBBB? Data from inherited diseases.

Inherited Cardiac Conduction Diseases (1) Progressive cardiac conduction defect (PCCD) is a frequent disease attributed to degeneration and fibrosis of the His bundle. Over the past years, gene defects have been identified demonstrating that PCCD could be a genetic disease as mutations in SCN5A, SCN1B and TRPM4 have been identified as the causal genes of inherited progressive cardiac conduction disease.

Inherited Cardiac Conduction Diseases (2) In a recent French study in families with CCD, progressive hemiblocks and RBBB were the most frequent conduction defects (44% and 33%, respectively). whereas LBBB was unfrequent (5%). Genetic predisposition to CCD seems to cause predominantly RBBB. Gourraud J B et al. Heart 2012;98:1305-1310

Inherited DCM + CCD caused by LAMIN A/C mutations The cardiac phenotype associated with LMNA mutations is characterized by atrial fibrillation, conduction disturbances, ventricular arrhythmias, and dilated cardiomyopathy In a meta-analysis of 299 carriers of a lamin A/C mutation (van Berlo et al J Mol Med 2005), 18% of patients less than 10 years of age had evidence of delayed intracardiac conduction. In patients over 30 years of age, 92% had conduction system disease, with 44% requiring pacemaker placement At variant with the genes implicated in CCD, Lamin A/C ia linked to LBBB.

Heritability of human electrocardiogram Heritability represents a relevant component of the human electrocardiogram In the general population, ECG intervals duration have on average 25-40% of their variability attributable to genetic factors. Single SNPs are usually associated with small effect. This implies the evaluation of large cohorts of patients in order to detect significant signals and differentiate them from noise. Genetics: Meta-analysis identifies variants in 22 loci associated with QRS duration. Osório J.Nat Rev Cardiol. 2011 Feb;8(2):

Pleiotropic associations of ECG variables Sotoodehnia N et al Nature Genetics 2010

GWAS of QRS complex duration in 40,407 healthy subjects Sotoodehnia N et al Nature Genetics 2010

SNPs that modulates the ECG predict SCD? ECG parameters like QRS duration and QTc duration influence the risk of SCD. Solid evidence from GWAS studies has shown that QRS and QT duration are modulated by common genetic variants CAN WE ASSUME THAT SCD IS INFLUENCED BY SNPs THAT MODULATE THE ECG?

WHEN SIZE MATTERS! Arking et al performed a genome-wide association metaanalysis in 1,283 SCD cases and >20,000 control individuals tested the role of 49 SNPs previously implicated in modulating electrocardiographic traits (QRS, QT, and RR intervals). Consistent with epidemiological studies showing increased risk of SCD with prolonged QRS/QT intervals, the interval-prolonging alleles are in aggregate associated with increased risk for SCD (P=0.006).

ECG modifiers and SCD: more complexity PLN (QT/QRS, p = 0.013) NOS1AP (QT, p = 0.010) KCNQ1 (QT, p =0.014) TKT/CACNA1D/PRKCD (QRS, p = 0.0007) SURPRISINGLY HOWEVER In TKT/CACNA1D/PRKCD and the QRS/QT interval prolonging allele is associated with decreased risk for SCD.

From QRS prolongation to SCD It is clear that SNPs do not act individualluy to modify a complex trait. SNPs are COMMON but their EFFECT is SMALL More modifiers occur at the same time and they may have opposite effects A summation of the influence of different SPNs will have to be taken in consideration

Is the combination of LBB and dyssynchrony able to modulate the trascriptome?

What is remodeling? Cardiac myocytes are able to react to biomechanical stress caused by pressure or volume load, reactive oxygen species, cytokines, circulating neurohormones. Biomechanical stress activates signalling pathways converging on transcription factors, co-regulators mrna that alter gene expression and induce hypertrophy and dysfunction.

The Molecular Signature of HF Gene expression changes create a Molecular Signature for HF that includes among several other changes decreased expression of alpha-myosin heavy chain sarcoplasmic-endoplasmic reticulum (αmhc), calcium ATPase 2-a (SERCA2a), phospholamban (PLB) and increased expression of brain natriuretic peptide (BNP). Therapeutic interventions such as beta-blockers and ACE inhibitors reverse the remodeling associated with HF. IS THERE A REMODELING ASSOCIATED WITH DYSSYNCHRONY IN HF?

Increase in SERCA during CRT Twenty heart failure patients were evaluted before and after CRT. Biopsy samples were obtained to assess the effect of CRT on gene expression profile (CANDIDATE GENES). CRT was associated with a significant upregulation of SERCA2alpha P =.01), PLN (P =.01), their ratio (P =.01), ratio of SERCA/NCX (P =.02), beta1-ar (P =.03), and APL (P =.01) mrna levels. Mullens W Heart Rhythm 2008

Remodeling and CRT 24 Pts NYHA Class III and IV receiving CRT were divided into 2 groups according to their response to CRT. (Responders= increase in EF of 25% & NYHA class >1) LV mrna levels of α-mhc, β-mhc and BNP, SERCA, and PLN were analyzed. RESPONDERS SHOWED SIGNIFCANT NORMALIZATION OF EXPRESSION PROFILES Vanderheyden M et al JACC 2008

LBB and the trascriptome In a canine model of LBBB ( ablation) and pacing leading to HF it has been possible to demonstrate the change in the expression profile of 1050 transcripts. Energy-deriving processes, including oxidative phosphorylation, tricarboxylic acid cycle, fatty acid and amino acid metabolism, were concomitantly downregulated in failing myocardium, whereas various cell signaling pathways and extracellular matrix components were upregulated.

Figure 1. KEGG pathway analysis in tachycardia pacing-induced heart failure. Barth A S et al. Circ Cardiovasc Genet 2009;2:371-378

Dyssynchrony increases heterogeneity in gene expression in the LV that is partially reduced by CRT. Barth A S et al. Circ Cardiovasc Genet 2009 Copyright American Heart Association

CONCLUSION 1: THE GENOME Genomic variants that influence QRS duration have also been associated with risk of SCD Some of them derive from GENES that cause Cardiac Conduction diseases, some others have been identified through GWAS studies HOWEVER interactions between SNPs has not been assessed carefully As far as the genetic basis of QRS in HF no studies have been conducted that allow to extrapolate findings obtained in the general population to HF patients.

CONCLUSION 2: THE TRANSCRIPTOME Animal studies showed that the PRE-SELECTION of genes that are likely to be differentially expressed provides a limited view on genetic remodeling. The same approach needs to be extended to human studies even if the inhertent difficultis make these studies complex. The major hurdle is represented by expression variations in genes that are still a functional mistery LOT OF WORK TO BE DONE BUT POTENTIALLY VERY REWARDING!